Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus IRBESARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus IRBESARTAN.
AVALIDE vs IRBESARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, thereby blocking vasoconstriction and aldosterone secretion.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
150 mg orally once daily; may increase to 300 mg once daily if needed.
None Documented
None Documented
Clinical Note
moderateIrbesartan + Benzydamine
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine."
Clinical Note
moderateIrbesartan + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Irbesartan."
Clinical Note
moderateIrbesartan + Droxicam
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam."
Clinical Note
moderateIrbesartan + Loxoprofen
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
The terminal elimination half-life of irbesartan is 11–15 hours, supporting once-daily dosing.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Irbesartan is primarily eliminated via biliary/fecal excretion (approximately 80%) and renal excretion (approximately 20%).
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen."